Market Research Life Sciences Market Research Pharmaceuticals Market Research Therapeutic Area Market Research Obstetrics/Gynecology Market Research

Europe Cervical Cancer Screening Market, Size, Forecast 2023-2028, Industry Trends, Growth, Share, Outlook, Impact of Inflation, Opportunity Company Analysis

Best Price Guarantee Length Publisher Published Date SKU
from $2,490 210 Pages Renub Research July, 2023 RNBR18068128
Best Price Guarantee
Price from $2,490
Length 210 Pages
Publisher Renub Research
Published Date July, 2023
SKU RNBR18068128

Europe Cervical Cancer Screening Market, Size, Forecast 2023-2028, Industry Trends, Growth, Share, Outlook, Impact of Inflation, Opportunity Company Analysis


Europe Cervical Cancer Screening Market is projected to reach a value of US$ 11.45 Billion by 2028, according to Renub Research. Within Europe, cervical cancer stands as the ninth most prevalent form of cancer affecting women, and it is the second leading cause of cancer-related deaths among women aged 15 to 44 years. Every year, more than 100,000 women in European Union countries receive a diagnosis of cervical cancer, a disease that serves as a significant indicator of the effectiveness of healthcare systems in managing cancer. The survival rates for cervical cancer are influenced by both early detection and the efficacy of treatment. Fortunately, cervical cancer is largely preventable when precancerous cells are identified and treated before they progress. The presence of the human papillomavirus (HPV) is responsible for over 90% of cervical cancer cases, making vaccination against the primary HPV types associated with cervical cancer crucial in reducing its incidence.

Europe Cervical Cancer Screening Market is estimated to expand with a CAGR of 4.02% during 2022-2028

European countries adopt diverse approaches to prevent and detect cervical cancer at an early stage. More than half of these countries have implemented screening programs that target the entire population. The mortality rates for cervical cancer in EU countries have experienced a decline, which can be attributed to improvements in incidence rates and survival rates. The incorporation of innovative features and technologies provides vendors with opportunities to attract fresh clientele and expand their market presence in emerging economies. This aspect is anticipated to be a driving force behind the growth of the cervical cancer diagnostic testing market in Europe. The escalating incidence of cervical cancer has heightened the demand for screening tests among women, emphasizing the importance of regular cervical cancer screening as a preventive measure.

The Europe cervical cancer screening process primarily involves two types of tests: the Pap test and HPV DNA testing. The Pap test involves the collection and examination of cervical cells for abnormalities after staining. HPV testing, on the other hand, focuses on detecting the presence of HPV infection in cells obtained from the cervix. Increasing awareness among women has led to a surge in the number of individuals opting for cervical cancer screening tests. The government has also played a significant role by organizing free medical camps, implementing health reimbursement schemes, and conducting awareness programs. Consequently, the number of cancer diagnostic centers and service providers has increased, contributing to the expansion of the cervical cancer screening industry.

Germany Pap test market is set to expand, making a positive impact on cervical cancer prevention due to its strong emphasis on women's health

Pap Smear Market, Europe cervical cancer screening industry is divided into United Kingdom, France, Germany, Italy, Spain, Sweden, Switzerland, Norway and Netherlands. The market for HPV testing and Pap tests in Germany is experiencing remarkable growth and development. As Germany places great emphasis on preventive healthcare, there is a growing demand for advanced screening methods to detect cervical cancer. HPV testing has gained prominence as a primary screening tool, alongside traditional Pap tests, due to its ability to detect high-risk HPV strains linked to cervical cancer. This has led to the introduction of innovative HPV testing technologies in the German market.

Moreover, Pap tests continue to be an integral part of cervical cancer screening protocols, with ongoing advancements in laboratory techniques and automation systems. With a well-established healthcare infrastructure and a proactive approach towards women's health, the HPV testing and Pap test market in Germany is poised for continued expansion and adoption.

Italy HPV DNA Test market is positioned for continued growth, making a significant impact on women's healthcare outcomes through its strong focus on cervical cancer prevention

HPV DNA Market, Europe cervical cancer screening industry is divided into United Kingdom, France, Germany, Italy, Spain, Sweden, Switzerland, Norway and Netherlands.The HPV DNA test market in Italy is experiencing significant growth and developments in upcoming years. Italy healthcare system places a strong emphasis on early detection and prevention of cervical cancer, driving the demand for HPV DNA testing. This advanced screening method detects the presence of high-risk human papillomavirus strains associated with cervical cancer, enabling timely interventions and reducing the disease burden. The market is characterized by technological advancements, including automated testing platforms and improved sample collection techniques, enhancing the accuracy and efficiency of HPV DNA tests in Italy. Government initiatives promoting regular screening programs and public awareness campaigns further contribute to the market's expansion. With its commitment to women's health and advancements in screening technology, the HPV DNA test market in Italy is poised for continued growth and success.

Key Company

The European cervical cancer screening industry is dominated by key market players such as Abbott Laboratories, Hologic Corporation, Becton, Siemens AG, Roche Diagnostics, Quest Diagnostics, and Cardinal Health. These companies play a vital role in shaping the industry landscape and driving advancements in cervical cancer screening technologies. With their expertise and innovative solutions, they contribute to the development of more accurate and efficient screening tests, ensuring early detection and improved patient outcomes. Through their research, development, and strategic initiatives, these market players continue to make significant contributions to the fight against cervical cancer in Europe.

Renub Research report titled “Europe Cervical Cancer Screening Market & Forecast, By Test Population and Market (Pap smear and HPV DNA), Countries (United Kingdom, France, Germany, Italy, Spain, Sweden, Switzerland, Norway and Netherlands), Company (Abbott Laboratories, Hologic Corporation, Becton, Siemens AG, Roche Diagnostics, Quest Diagnostics, and Cardinal Health)” provides a complete analysis of Europe Cervical Cancer Screening Industry.

Cervical Cancer Diagnostics Market has been covered from 2 viewpoints:

1. Pap Smear Tests Market
2. HPV DNA Tests Market

Cervical Cancer Test Population has been covered from 2 viewpoints:

1. Pap Smear Test Population
2. HPV DNA Test Population

All the 9 Countries Studied in the Europe Cervical Cancer Screening Market Report is as Follows

1. United Kingdom
2. France
3. Germany
4. Italy
5. Spain
6. Sweden
7. Switzerland
8. Norway
9. Netherland

All companies have been covered with 3 viewpoints

• Overviews
• Recent Developments
• Revenues

Company Analysis:-

1. Abbott Laboratories
2. Hologic Corporation
3. Becton, Siemens AG
4. Roche Diagnostics
5. Quest Diagnostics
6. Cardinal Health


1. Introduction
2. Research Methodology
3. Executive Summary
4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges
5. Porter’s Five Forces
5.1 Bargaining Power of Buyer
5.2 Bargaining Power of Supplier
5.3 Threat of New Entrants
5.4 Rivalry among Existing Competitors
5.5 Threat of Substitute Products
6. SWOT Analysis
6.1 Strengths
6.2 Weaknesses
6.3 Opportunities
6.4 Threats
7. Europe Cervical Cancer Screening Analysis
7.1 Europe Cervical Cancer Market
7.2 Europe Cervical Cancer Population
8. Europe Cervical Cancer Test (Screening) Analysis
8.1 Europe Cervical Cancer Test Population
8.1.1 Pap smear Test Population
8.1.2 HPV DNA Test Population
8.2 Europe Cervical Cancer Test (Screening) Market
8.2.1 Pap Smear Test Market
8.2.2 HPV DNA Test Market
9. By Countries - Europe Cervical Cancer TestMarket &Population Share Analysis
9.1 Europe Cervical Cancer Test Population Share
9.1.1 Pap Smear Population
9.1.2 HPV DNA Population
9.2 Europe Cervical Cancer Market Share
9.2.1 Pap Smear Market
9.2.2 HPV DNA Market
10. United Kingdom – Cervical Cancer Test Analysis
10.1 Population – Cervical Cancer Test (Screening)
10.1.1 Pap smear Test Population
10.1.2 HPV DNA Test Population
10.2 Market – Cervical Cancer Test (Screening)
10.2.1 Pap smear Test Market
10.2.2 HPV DNA Test Market
11. France – Cervical Cancer Test Analysis
11.1 Population – Cervical Cancer Test (Screening)
11.1.1 Pap smear Test Population
11.1.2 HPV DNA Test Population
11.2 Market – Cervical Cancer Test (Screening)
11.2.1 Pap Smear Test Market
11.2.2 HPV DNA Test Market
12. Germany – Cervical Cancer Test Analysis
12.1 Population – Cervical Cancer Test (Screening)
12.1.1 Pap smear Test Population
12.1.2 HPV DNA Test Population
12.2 Market – Cervical Cancer Test (Screening)
12.2.1 Pap Smear Test Market
12.2.2 HPV DNA Test Market
13. Italy – Cervical Cancer Test Analysis
13.1 Population – Cervical Cancer Test (Screening)
13.1.1 Pap smear Test Population
13.1.2 HPV DNA Test Population
13.2 Market – Cervical Cancer Test (Screening)
13.2.1 Pap Smear Test Market
13.2.2 HPV DNA Test Market
14. Spain – Cervical Cancer Test Analysis
14.1 Population – Cervical Cancer Test (Screening)
14.1.1 Pap smear Test Population
14.1.2 HPV DNA Test Population
14.2 Market – Cervical Cancer Test (Screening)
14.2.1 Pap Smear Test Market
14.2.2 HPV DNA Test Market
15. Sweden – Cervical Cancer Test Analysis
15.1 Population – Cervical Cancer Test (Screening)
15.1.1 Pap smear Test Population
15.1.2 HPV DNA Test Population
15.2 Market – Cervical Cancer Test (Screening)
15.2.1 Pap Smear Test Market
15.2.2 HPV DNA Test Market
16. Switzerland – Cervical Cancer Test Analysis
16.1 Population – Cervical Cancer Test (Screening)
16.1.1 Pap smear Test Population
16.1.2 HPV DNA Test Population
16.2 Market – Cervical Cancer Test (Screening)
16.2.1 Pap Smear Test Market
16.2.2 HPV DNA Test Market
17. Norway – Cervical Cancer Test Analysis
17.1 Population – Cervical Cancer Test (Screening)
17.1.1 Pap smear Test Population
17.1.2 HPV DNA Test Population
17.2 Market – Cervical Cancer Test (Screening)
17.2.1 Pap Smear Test Market
17.2.2 HPV DNA Test Market
18. Netherlands – Cervical Cancer Test Analysis
18.1 Population – Cervical Cancer Test (Screening)
18.1.1 Pap smear Test Population
18.1.2 HPV DNA Test Population
18.2 Market – Cervical Cancer Test (Screening)
18.2.1 Pap Smear Test Market
18.2.2 HPV DNA Test Market
19. Company Analysis
19.1 Abbott laboratories
19.1.1 Overview
19.1.2 Recent Development
19.1.3 Revenue
19.2 Hologic Corporation
19.2.1 Overview
19.2.2 Recent Development
19.2.3 Revenue
19.3 Becton
19.3.1 Overview
19.3.2 Recent Development
19.3.3 Revenue
19.4 Siemens AG
19.4.1 Overview
19.4.2 Recent Development
19.4.3 Revenue
19.5 Roche Diagnostics
19.5.1 Overview
19.5.2 Recent Development
19.5.3 Revenue
19.6 Quest Diagnostics
19.6.1 Overview
19.6.2 Recent Development
19.6.3 Revenue
19.7 Cardinal Health
19.7.1 Overview
19.7.2 Recent Development
19.7.3 Revenue
List of Figures:
Figure-01: Europe – Cervical Cancer Test (Screening) Market (Billion US$), 2018 – 2022
Figure-02: Europe – Forecast for Cervical Cancer Test (Screening) Market (Billion US$), 2023 – 2028
Figure-03: Europe – Cervical Cancer Test (Screening) Population Volume (Million), 2018 – 2022
Figure-04: Europe – Forecast for Cervical Cancer Test (Screening) Population Volume (Million), 2023 – 2028
Figure-05: Europe – Pap Smear Test (Screening) Population Volume (Million), 2018 – 2022
Figure-06: Europe – Forecast for Pap Smear Test (Screening) Population Volume (Million), 2023 – 2028
Figure-07: Europe – HPV DNA Test (Screening) Population Volume (Million), 2018 – 2022
Figure-08: Europe – Forecast for HPV DNA Test (Screening) Population Volume (Million), 2023 – 2028
Figure-09: Europe – Pap Smear Test (Screening) Market (Million US$), 2018 – 2022
Figure-10: Europe – Forecast for Pap Smear Test (Screening) Market (Million US$), 2023 – 2028
Figure-11: Europe – HPV DNA Test (Screening) Market (Million US$), 2018 – 2022
Figure-12: Europe – Forecast for HPV DNA Test (Screening) Market (Million US$), 2023 – 2028
Figure-13: United Kingdom – Pap Smear Test (Screening) Population Volume (Thousand), 2018 – 2022
Figure-14: United Kingdom – Forecast for Pap Smear Test (Screening) Population Volume (Thousand), 2023 – 2028
Figure-15: United Kingdom – HPV DNA Test (Screening) Population Volume (Thousand), 2018 – 2022
Figure-16: United Kingdom – Forecast for HPV DNA Test (Screening) Population Volume (Thousand), 2023 – 2028
Figure-17: United Kingdom – Pap Smear Test (Screening) Market (Million US$), 2018 – 2022
Figure-18: United Kingdom – Forecast for Pap Smear Test (Screening) Market (Million US$), 2023 – 2028
Figure-19: United Kingdom – HPV DNA Test (Screening) Market (Million US$), 2018 – 2022
Figure-20: United Kingdom – Forecast for HPV DNA Test (Screening) Market (Million US$), 2023 – 2028
Figure-21: France – Pap Smear Test (Screening) Population Volume (Thousand), 2018 – 2022
Figure-22: France – Forecast for Pap Smear Test (Screening) Population Volume (Thousand), 2023 – 2028
Figure-23: France – HPV DNA Test (Screening) Population Volume (Thousand), 2018 – 2022
Figure-24: France – Forecast for HPV DNA Test (Screening) Population Volume (Thousand), 2023 – 2028
Figure-25: France – Pap Smear Test (Screening) Market (Million US$), 2018 – 2022
Figure-26: France – Forecast for Pap Smear Test (Screening) Market (Million US$), 2023 – 2028
Figure-27: France – HPV DNA Test (Screening) Market (Million US$), 2018 – 2022
Figure-28: France – Forecast for HPV DNA Test (Screening) Market (Million US$), 2023 – 2028
Figure-29: Germany – Pap Smear Test (Screening) Population Volume (Thousand), 2018 – 2022
Figure-30: Germany – Forecast for Pap Smear Test (Screening) Population Volume (Thousand), 2023 – 2028
Figure-31: Germany – HPV DNA Test (Screening) Population Volume (Thousand), 2018 – 2022
Figure-32: Germany – Forecast for HPV DNA Test (Screening) Population Volume (Thousand), 2023 – 2028
Figure-33: Germany – Pap Smear Test (Screening) Market (Million US$), 2018 – 2022
Figure-34: Germany – Forecast for Pap Smear Test (Screening) Market (Million US$), 2023 – 2028
Figure-35: Germany – HPV DNA Test (Screening) Market (Million US$), 2018 – 2022
Figure-36: Germany – Forecast for HPV DNA Test (Screening) Market (Million US$), 2023 – 2028
Figure-37: Italy – Pap Smear Test (Screening) Population Volume (Thousand), 2018 – 2022
Figure-38: Italy – Forecast for Pap Smear Test (Screening) Population Volume (Thousand), 2023 – 2028
Figure-39: Italy – HPV DNA Test (Screening) Population Volume (Thousand), 2018 – 2022
Figure-40: Italy – Forecast for HPV DNA Test (Screening) Population Volume (Thousand), 2023 – 2028
Figure-41: Italy – Pap Smear Test (Screening) Market (Million US$), 2018 – 2022
Figure-42: Italy – Forecast for Pap Smear Test (Screening) Market (Million US$), 2023 – 2028
Figure-43: Italy – HPV DNA Test (Screening) Market (Million US$), 2018 – 2022
Figure-44: Italy – Forecast for HPV DNA Test (Screening) Market (Million US$), 2023 – 2028
Figure-45: Spain – Pap Smear Test (Screening) Population Volume (Thousand), 2018 – 2022
Figure-46: Spain – Forecast for Pap Smear Test (Screening) Population Volume (Thousand), 2023 – 2028
Figure-47: Spain – HPV DNA Test (Screening) Population Volume (Thousand), 2018 – 2022
Figure-48: Spain – Forecast for HPV DNA Test (Screening) Population Volume (Thousand), 2023 – 2028
Figure-49: Spain – Pap Smear Test (Screening) Market (Million US$), 2018 – 2022
Figure-50: Spain – Forecast for Pap Smear Test (Screening) Market (Million US$), 2023 – 2028
Figure-51: Spain – HPV DNA Test (Screening) Market (Million US$), 2018 – 2022
Figure-52: Spain – Forecast for HPV DNA Test (Screening) Market (Million US$), 2023 – 2028
Figure-53: Sweden – Pap Smear Test (Screening) Population Volume (Thousand), 2018 – 2022
Figure-54: Sweden – Forecast for Pap Smear Test (Screening) Population Volume (Thousand), 2023 – 2028
Figure-55: Sweden – HPV DNA Test (Screening) Population Volume (Thousand), 2018 – 2022
Figure-56: Sweden – Forecast for HPV DNA Test (Screening) Population Volume (Thousand), 2023 – 2028
Figure-57: Sweden – Pap Smear Test (Screening) Market (Million US$), 2018 – 2022
Figure-58: Sweden – Forecast for Pap Smear Test (Screening) Market (Million US$), 2023 – 2028
Figure-59: Sweden – HPV DNA Test (Screening) Market (Million US$), 2018 – 2022
Figure-60: Sweden – Forecast for HPV DNA Test (Screening) Market (Million US$), 2023 – 2028
Figure-61: Switzerland – Pap Smear Test (Screening) Population Volume (Thousand), 2018 – 2022
Figure-62: Switzerland – Forecast for Pap Smear Test (Screening) Population Volume (Thousand), 2023 – 2028
Figure-63: Switzerland – HPV DNA Test (Screening) Population Volume (Thousand), 2018 – 2022
Figure-64: Switzerland – Forecast for HPV DNA Test (Screening) Population Volume (Thousand), 2023 – 2028
Figure-65: Switzerland – Pap Smear Test (Screening) Market (Million US$), 2018 – 2022
Figure-66: Switzerland – Forecast for Pap Smear Test (Screening) Market (Million US$), 2023 – 2028
Figure-67: Switzerland – HPV DNA Test (Screening) Market (Million US$), 2018 – 2022
Figure-68: Switzerland – Forecast for HPV DNA Test (Screening) Market (Million US$), 2023 – 2028
Figure-69: Norway – Pap Smear Test (Screening) Population Volume (Thousand), 2018 – 2022
Figure-70: Norway – Forecast for Pap Smear Test (Screening) Population Volume (Thousand), 2023 – 2028
Figure-71: Norway – HPV DNA Test (Screening) Population Volume (Thousand), 2018 – 2022
Figure-72: Norway – Forecast for HPV DNA Test (Screening) Population Volume (Thousand), 2023 – 2028
Figure-73: Norway – Pap Smear Test (Screening) Market (Million US$), 2018 – 2022
Figure-74: Norway – Forecast for Pap Smear Test (Screening) Market (Million US$), 2023 – 2028
Figure-75: Norway – HPV DNA Test (Screening) Market (Million US$), 2018 – 2022
Figure-76: Norway – Forecast for HPV DNA Test (Screening) Market (Million US$), 2023 – 2028
Figure-77: Netherlands – Pap Smear Test (Screening) Population Volume (Thousand), 2018 – 2022
Figure-78: Netherlands – Forecast for Pap Smear Test (Screening) Population Volume (Thousand), 2023 – 2028
Figure-79: Netherlands – HPV DNA Test (Screening) Population Volume (Thousand), 2018 – 2022
Figure-80: Netherlands – Forecast for HPV DNA Test (Screening) Population Volume (Thousand), 2023 – 2028
Figure-81: Netherlands – Pap Smear Test (Screening) Market (Million US$), 2018 – 2022
Figure-82: Netherlands – Forecast for Pap Smear Test (Screening) Market (Million US$), 2023 – 2028
Figure-83: Netherlands – HPV DNA Test (Screening) Market (Million US$), 2018 – 2022
Figure-84: Netherlands – Forecast for HPV DNA Test (Screening) Market (Million US$), 2023 – 2028
Figure-85: Abbott laboratories – Global Revenue (Billion US$), 2018 – 2022
Figure-86: Abbott laboratories – Forecast for Global Revenue (Billion US$), 2023 – 2028
Figure-87: Hologic Corporation – Global Revenue (Billion US$), 2018 – 2022
Figure-88: Hologic Corporation – Forecast for Global Revenue (Billion US$), 2023 – 2028
Figure-89: Becton – Global Revenue (Billion US$), 2018 – 2022
Figure-90: Becton – Forecast for Global Revenue (Billion US$), 2023 – 2028
Figure-91: Siemens AG – Global Revenue (Billion US$), 2018 – 2022
Figure-92: Siemens AG – Forecast for Global Revenue (Billion US$), 2023 – 2028
Figure-93: Roche Diagnostics – Global Revenue (Billion US$), 2018 – 2022
Figure-94: Roche Diagnostics – Forecast for Global Revenue (Billion US$), 2023 – 2028
Figure-95: Quest Diagnostics – Global Revenue (Billion US$), 2018 – 2022
Figure-96: Quest Diagnostics – Forecast for Global Revenue (Billion US$), 2023 – 2028
Figure-97: Cardinal Health – Global Revenue (Billion US$), 2018 – 2022
Figure-98: Cardinal Health – Forecast for Global Revenue (Billion US$), 2023 – 2028
List of Tables:
Table-01: Europe – Pap Smear Test (Screening) Population Volume Share by Country (Percent), 2018 – 2022
Table-02: Europe – Forecast for Pap Smear Test (Screening) Population Volume Share by Country (Percent), 2023 – 2028
Table-03: Europe – HPV DNA Test (Screening) Population Volume Share by Country (Percent), 2018 – 2022
Table-04: Europe – Forecast for HPV DNA Test (Screening) Population Volume Share by Country (Percent), 2023 – 2028
Table-05: Europe – Pap Smear Test (Screening) Market Share by Country (Percent), 2018 – 2022
Table-06: Europe – Forecast for Pap Smear Test (Screening) Market Share by Country (Percent), 2023 – 2028
Table-07: Europe – HPV DNA Test (Screening) Market Share by Country (Percent), 2018 – 2022
Table-08: Europe – Forecast for HPV DNA Test (Screening) Market Share by Country (Percent), 2023 – 2028

$2,490
$3,490

Research Assistance

US: 800.298.5699
Int'l: +1.240.747.3093
Live help
Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Other tasks

Cookie Settings